

The San Francisco Hepatitis C Elimination Initiative, End Hep C SF, is a multi-sector collective impact initiative that utilizes evidence-based practices, community wisdom, and the creative leveraging of resources to work toward hepatitis C elimination in San Francisco.^{1,2,3}

San Francisco has a history of innovative and ambitious public health efforts. End Hep C SF emerges from that history to tackle an epidemic that kills more Americans than the deaths from sixty other reportable infectious diseases, including HIV, pneumococcal disease, and tuberculosis, combined.^{4,5}

Vision Statement

San Francisco is profoundly impacted by the hepatitis C virus (HCV), a communicable liver disease that is a significant driver of morbidity, liver cancer, and death. The availability of highly effective, well-tolerated oral HCV therapy gives us the remarkable ability to cure HCV in nearly all people living with the virus. We now have the tools to greatly reduce the negative health consequences of HCV, to break the cycle of forward transmission through cure as prevention, and to ultimately eliminate HCV in San Francisco. To realize the potential of modern HCV therapy, we have established End Hep C SF. Our long-term strategic plan is to lay the foundation for HCV elimination in San Francisco through a comprehensive approach based on three pillars:


- Citywide community-based HCV testing for highly impacted populations paired with augmented HCV surveillance infrastructure to track the HCV epidemic and progress towards elimination;
- Linkage to care and treatment access for all people living with HCV;
- 3. Prevention of new HCV infections and reinfection in those cured of HCV.

1. Elimination refers to the cessation of transmission of a disease in a single country, continent, or other limited geographic area, rather than global eradication (e.g., polio in the Americas).

- Collective Impact is a framework to tackle deeply entrenched and complex social problems. It is an innovative and structured approach to making collaboration work across government, business, philanthropy, non-profit organizations and citizens to achieve significant and lasting social change.
- 3. <u>http://www.collaborationforimpact.com</u>
- Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003–2013 Clin Infect Dis. first published online March 1, 2016 doi:10.1093/cid/ciw111
- 5. http://www.cdc.gov/media/releases/2016/p0504-hepc-mortality.html

Community Partners

UCSF Alliance Health Project **BAART Programs Bayyiew Hunters Point Foundation** California Hepatitis Alliance (CalHEP) **Drug Policy Alliance Facente Consulting Glide Foundation** Harm Reduction Coalition HealthRIGHT 360 Hellman Foundation Homeless Youth Alliance Kaiser Permanente Larkin Street Youth Services Mission Neighborhood Health Center Mission Wellness Pharmacy Native American Health Center **Opiate Treatment Outpatient Program (OTOP)** Positive Health Program **Project Open Hand RTI** International San Francisco AIDS Foundation San Francisco Community Health Center San Francisco Cancer Initiative (SF CAN) San Francisco Department of Public Health San Francisco Health Plan San Francisco Hepatitis C Task Force Shanti Project South of Market Health Center St. James Infirmary Sutter Health UCSF UCSF NOW (No One Waits) Study The UFO Study Walgreens Zuckerberg San Francisco General Hospital



Committees and Work Groups

End Hep C SF is guided by a Coordinating Committee and four topic-specific work groups that recommend action steps to the Coordinating Committee. The Work Groups are comprised of individuals affected by HCV, healthcare and social service providers, community advocates, health department representatives, and other stakeholders. The Work Groups include: Policy & Advocacy; Prevention, Testing & Linkage; Research & Surveillance; and Treatment Access. The lifeblood of our initiative is our community members, especially those who have lived experience with HCV. We continuously strive to improve representation and build leadership in our initiative so that community members guide this work at all levels, and we believe in appropriate compensation for their labor and expertise.

Coordinating Committee Members

Katie Burk, MPH - SFDPH Joanne Kay - End Hep C SF Shelley Facente, MPH - Facente Consulting Perry Rhodes III - Alliance Health Project Jordan Akerley - The Shanti Project Amy Rodriguez - Glide Annie Luetkemeyer, MD, UCSF Jennifer Price, MD - UCSF Meghan Morris, PhD - UCSF / UFO Study Melissa Sanchez, PhD - SFDPH Robin Roth - San Francisco Hepatitis C Task Force Pauli Gray - San Francisco Hepatitis C Task Force Isaac Jackson, Urban Survivors Union Miss Ian - Drug Users' Union Brian Clear, MD - BAART Programs Courtney Mulhern-Pearson, MPH - SF AIDS Fdn